Approval of First BTK Inhibitor to Treat Pediatric Graft-Versus-Host Disease
Ibrutinib, a small molecule inhibitor of B-cell proliferation, was approved for pediatric patients with chronic graft-versus-host disease. The U.S. Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) for pediatric patients 1 year of...